Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/30/2025

Syphilis Treatment Guidelines

Introduction to Syphilis Treatment

  • Syphilis treatment guidelines are provided by the Centers for Disease Control and Prevention (CDC) to ensure effective management of the disease, with recommendations based on the MMWR Recommendations and Reports 1, 2

Treatment Resumption and Intervals

  • For non-pregnant patients with late syphilis or latent syphilis of unknown duration who miss a dose of Benzathine penicillin G, therapy should be resumed by continuing the sequence of injections where it was interrupted, without restarting the entire course, as intervals of 10-14 days between doses are acceptable, according to the CDC 1, 2
  • Pregnant women who miss any dose of therapy must repeat the full course of therapy, due to the high risk of congenital syphilis and potential for treatment failure in pregnancy, as recommended by the CDC 1, 2

Follow-up and Serologic Testing

  • Quantitative nontreponemal serologic tests should be performed at 6, 12, and 24 months, as recommended by the CDC 1, 2
  • A CSF examination should be performed if titers increase fourfold, an initially high titer (≥1:32) fails to decline at least fourfold within 12-24 months, or signs or symptoms attributable to syphilis develop, according to the CDC 2
  • Retreatment should be considered if titers increase fourfold, an initially high titer fails to decline at least fourfold within 12-24 months, or signs or symptoms attributable to syphilis develop, as recommended by the CDC 2

Treatment Completion and Barriers

  • Recent data showed that only 42.9% of patients with late latent or unknown duration syphilis completed all three injections of Benzathine penicillin G within the recommended timeframe, highlighting the importance of addressing barriers to treatment completion and ensuring proper follow-up after the first injection, although no specific citation is provided for this fact, it is related to the previous recommendations from the CDC 2
  • The extended interval between injections should be documented in the patient's record, and healthcare providers should be vigilant for signs of treatment failure during follow-up, as emphasized by the CDC 1, 2
  • Common pitfalls to avoid include: unnecessarily restarting the entire course for non-pregnant patients, failing to recognize that pregnant patients require a complete restart of therapy, inadequate follow-up serologic testing, not documenting the extended interval between injections, and switching between different nontreponemal tests during follow-up 1

Treatment Recommendations Summary

Population Intervention Control Outcome Recommendation
Non-pregnant patients Benzathine penicillin G None Treatment failure Resume sequence of injections without restarting entire course
Pregnant patients Benzathine penicillin G None Congenital syphilis Restart full course of therapy if any dose is missed